Could a noninvasive, cutting-edge radiation therapy for cancer also be used to treat heart arrhythmias? Mayo Clinic researchers think so.

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.09 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to earnings of $1.73 per share a year ago. These ...

Enrollment Target for Adult Sickle Cell Disease Patients Achieved in BEACON Trial ofBEAM-101; Dosing of 30 Patients and Updated Data Expected by ...

Proton arc therapy offers a superior dose distribution compared with existing state-of-the-art proton delivery techniques ...

Beam expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable the company to fund its anticipated ...

What do rope winding and giant pasta shapes have to do with particle physics? The answer is a new superconducting magnet ...

New data show that external-beam radiation therapy yielded superior local control and progression-free survival vs TACE in ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...

Ark Invest, through its ARK Fintech Innovation ETF ARKF -5.46% + Free Alerts , bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark’s ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

J. Scott Cordova, M.D., Ph.D., has joined the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller ...